FCX vs SNDX · P/E 38, rev $13.26B vs rev $137.7M
Freeport-McMoran Copper & Gold Inc (FCX) versus Syndax Pharmaceuticals Inc (SNDX) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Syndax Pharmaceuticals Inc (SNDX) is a biotechnology company listed on US.
Latest reported FCX revenue for 2026-06-30 was $13.26B. Net income was $1.86B. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported SNDX revenue for 2026-06-30 was $137.7M. Net income was -$92.0M. SNDX currently screens at market cap $774.4M.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. SNDX currently screens at market cap $774.4M.
Not investment advice. Open the FCX and SNDX stock pages for the full models.
Not investment advice.